Pierre HAEN

Dr. Pierre HAEN

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PHPierre HAEN
Pierre HAEN
DMDiane Mege
Diane Mege
LCLydie Crescence
Lydie Crescence
FDFrançoise Dignat-George
Françoise Dignat-George
Christophe DuboisChristophe Dubois
Christophe Dubois
LPLaurence Panicot-Dubois
Laurence Panicot-Dubois
Venous thromboembolism (VTE) is a common complication for cancer patients. VTE-associated risk varies according to the type of tumor disease. Head and neck cancer is a common cancer worldwide, and most tumors are squamous cell carcinomas due to tobacco and alcohol abuse. The risk of VTE associated with head and neck (H&N) cancer is considered empirically low, but despite the high incidence of H&N cancer, few data are available on this cancer; thus, it is difficult to state the risk of VTE. Our review aims to clarify this situation and tries to assess the real VTE risk associated with H&N cancer. We report that most clinical studies have concluded that there is a very low thrombosis risk associated with H&N cancer. Even with the biases that often exist, this clinical review seems to confirm that the risk of VTE was empirically hypothesized. Furthermore, we highlight that H&N cancer has all the biological features of a cancer associated with a high thrombosis risk, including a strong expression of procoagulant proteins, modified thrombosis/fibrinolysis mechanisms, and secretions of procoagulant microparticles and procoagulant cytokines. Thus, this is a paradoxical situation, and some undiscovered mechanisms that could explain this clinical biological ambivalence might exist.

1 September 2021 in Journal of Stomatology Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
RKRoman Hossein Khonsari
Roman Hossein Khonsari
JAJeremy Adam
Jeremy Adam
MBMourad Benassarou
Mourad Benassarou
HBHélios Bertin
Hélios Bertin
BBBenjamin Billotet
Benjamin Billotet
CMChristophe Meyer
Christophe Meyer

1 April 2019 in Journal of Stomatology Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
JFJ.M. Foletti
J.M. Foletti
VMV. Martinez
V. Martinez
PHPierre HAEN
Pierre HAEN
YGY. Godio-Raboutet
Y. Godio-Raboutet
LGL. Guyot
L. Guyot
LTL. Thollon
L. Thollon

1 February 2018 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Closed access
PHPierre HAEN
Pierre HAEN
GDGuillaume Dubois
Guillaume Dubois
PGPatrick Goudot
Patrick Goudot
TSThomas Schouman
Thomas Schouman

24 February 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
PHPierre HAEN
Pierre HAEN
LCLydie Crescence
Lydie Crescence
DMDiane Mege
Diane Mege
AAAlexandre Altié
Alexandre Altié
Christophe DuboisChristophe Dubois
Christophe Dubois
LPLaurence Panicot-Dubois
Laurence Panicot-Dubois
Venous thrombo-embolism (VTE) disease is the second most common cause of mortality in cancer patients, and evaluation and prevention of thrombosis risk is essential. VTE-associated risk varies according to the type of tumor disease. Oral cancer is the most frequent type of head and neck cancer, and it represents approximately 2.1% of all cancers worldwide. Most tumors are squamous cell carcinomas and are mainly due to tobacco and alcohol abuse. VTE risk associated with oral squamous cell carcinoma (OSCC) is low. However, many studies have shown that OSCC has the following biological features of cancers associated with a high thrombosis risk: modified thrombosis and fibrinolysis mechanisms; strong expression of procoagulant proteins; secretion of procoagulant microparticles; and production of procoagulant cytokines. Using an original mouse model of tongue squamous cell carcinoma, our study aimed to clarify this paradoxical situation. First, we showed that OSCC tumors have a pro-aggregatory phenotype and a high local thrombosis risk. Second, we found that tongue tumor mice do not have an elevated systemic thrombosis risk (the risk of an “at distance” thrombosis event such as lower extremity deep venous thrombosis or pulmonary embolism) and even show a reduction in risk. Third, we demonstrated that tongue tumor mice show a reduction in platelet reactivity, which explains the low systemic thrombosis risk. Finally, we found that tongue tumor mice present granule pool deficiency, thereby explaining the reduction in platelet reactivity and systemic thrombosis risk.

1 June 2020 in Oral Oncology
Verified
Journal Article
Closed access
PHPierre HAEN
Pierre HAEN
JCJean-Baptiste Caruhel
Jean-Baptiste Caruhel
SLSophie Laversanne
Sophie Laversanne
PCPierre-Yves Cordier
Pierre-Yves Cordier